UY-Adult Urology

Medicine & Life Sciences

1. Robotics 100%
2. Renal Cell Carcinoma 92%
3. Nephroureterectomy 91%
4. Carcinoma 75%
5. Artificial Urinary Sphincter 57%
6. Neoplasms 55%
7. Nephrectomy 52%
8. Kidney 51%
9. Prostatectomy 49%
10. Urinary Bladder Neoplasms 47%
11. Prostate 46%
12. Penile Prosthesis 44%
13. Biopsy 42%
14. Survival 41%
15. Lymph Node Excision 40%
16. Stress Urinary Incontinence 34%
17. Recurrence 32%
18. Multiparametric Magnetic Resonance Imaging 31%
19. Drug Therapy 30%
20. Urinary Bladder 30%
21. Kidney Neoplasms 29%
22. Urology 27%
23. Cystectomy 26%
24. Therapeutics 26%
25. Germ Cell and Embryonal Neoplasms 25%
26. Radiosurgery 22%
27. Prostatic Neoplasms 22%
28. Testicular Germ Cell Tumor 21%
29. Magnetic Resonance Imaging 19%
30. Safety 19%
31. Inferior Vena Cava 19%
32. Surgeons 19%
33. Costs and Cost Analysis 18%
34. Urethral Stricture 18%
35. Suburethral Slings 18%
36. Testicular Neoplasms 17%
37. Nonseminomatous germ cell tumor 17%
38. Quality of Life 16%
39. Databases 16%
40. Urinary Tract 14%
41. Internship and Residency 14%
42. Prostatic Hyperplasia 13%
43. Nomograms 13%
44. Nephrolithiasis 13%
45. Thrombosis 13%
46. Neoplasm Metastasis 13%
47. Ureter 12%
48. Safety-net Providers 12%
49. Immunotherapy 12%
50. Cystoscopy 12%
51. Cisplatin 11%
52. Kidney Calculi 11%
53. Operative Time 11%
54. Hot Temperature 11%
55. United States Food and Drug Administration 11%
56. Ureteroscopy 11%
57. Orchiectomy 11%
58. Electroporation 11%
59. Radiofrequency Ablation 10%
60. Pathologic Constriction 10%
61. Propensity Score 10%
62. Confidence Intervals 10%
63. Renal Colic 10%
64. Demography 10%
65. Systematic Reviews 10%
66. Histology 10%
67. Logistic Models 10%
68. BRCA1 Protein 10%
69. Stents 9%
70. Nephrons 9%
71. Penile Neoplasms 9%
72. Registries 9%
73. Equipment and Supplies 9%
74. Muscles 9%
75. Magnets 8%
76. Reoperation 8%
77. Urinary Diversion 8%
78. Pathology 8%
79. Morbidity 8%
80. Hematuria 8%
81. Minimally Invasive Surgical Procedures 8%
82. Seminoma 8%
83. Mitomycin 8%
84. 5-alpha Reductase Inhibitors 7%
85. Gels 7%
86. Meta-Analysis 7%
87. Urethral Diseases 7%
88. Globulins 7%
89. Pain 7%
90. Tertiary Care Centers 7%
91. Regression Analysis 7%
92. Metastasectomy 7%
93. Cough 7%
94. Pelvic Organ Prolapse 7%
95. Pandemics 7%
96. Body Mass Index 7%
97. Guidelines 7%
98. Wounds and Injuries 7%
99. Bacillus 7%
100. Prostate-Specific Antigen 7%